Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK1D | Q8IU85 | 15/20 | 0.54 |
| ▸ | SYK | P43405 | 5/20 | 0.53 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RIPK4 | P57078 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.53 |
| ▸ | CAMK1 | Q14012 | 1/20 | 0.53 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.53 |
| ▸ | PNCK | Q6P2M8 | 1/20 | 0.53 |
| ▸ | CAMK1G | Q96NX5 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12085272 | 0.85 | SYK (0.48) | CAMK1DSYKPIP5K1CCYP2C9CYP2C19 | |
| SCHEMBL12085349 | 0.82 | CAMK1D (0.66) | CAMK1DPIP5K1CCYP2C9CYP2C19RIPK4 | |
| SCHEMBL12085360 | 0.81 | CAMK1D (0.57) | CAMK1DSYKPIP5K1CCYP2C9CYP2C19 | |
| SCHEMBL8319810 | 0.75 | EGFR (0.57) | — | |
| SCHEMBL12085289 | 0.74 | SYK (0.50) | CAMK1DSYKPIP5K1CCYP2C9CYP2C19 | |
| SCHEMBL2627319 | 0.73 | SYK (0.64) | SYK | |
| SCHEMBL15515804 | 0.72 | ELANE (0.40) | SYK | |
| SCHEMBL15508946 | 0.72 | ELANE (0.40) | SYK | |
| SCHEMBL15509236 | 0.72 | ELANE (0.40) | SYK | |
| SCHEMBL12085331 | 0.71 | CAMK1D (0.62) | CAMK1DSYKRIPK4KCNH2MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK2 | CAMK1D 778/4885SYK 1/4885PIP5K1C 115/4885 |
| US-20090298823-A1 | Inhibitors of protein kinases | SYK, BTK, JAK2 | CAMK1D 778/4885SYK 1/4885PIP5K1C 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.